Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20-positive B Cell Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02867566
What this trial is testing

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Who this might be right for
Diffuse, Large B-Cell, Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 420
Testing effectiveness (Phase 2)UnknownNCT05771883
What this trial is testing

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Who this might be right for
B-cell Non-Hodgkin's Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 102
Large-scale testing (Phase 3)Ended earlyNCT00169169
What this trial is testing

Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

Who this might be right for
CD20-Positive Large B-Cell Lymphoma
Lymphoma Study Association 430
Large-scale testing (Phase 3)Study completedNCT01649856
What this trial is testing

Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Hoffmann-La Roche 572
Testing effectiveness (Phase 2)UnknownNCT00397800
What this trial is testing

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Technical University of Munich 12
Early research (Phase 1)Temporarily pausedNCT04746131
What this trial is testing

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

Who this might be right for
B-cell Non-Hodgkin's Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 90
Early research (Phase 1)Ended earlyNCT03670888
What this trial is testing

Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

Who this might be right for
B Cell Lymphoma
JHL Biotech, Inc. 1
Testing effectiveness (Phase 2)UnknownNCT00385125
What this trial is testing

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Who this might be right for
Lymphoma, High-Grade
University of Magdeburg 30
Early research (Phase 1)Active Not RecruitingNCT04007029
What this trial is testing

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic Leukemia+11 more
Jonsson Comprehensive Cancer Center 24
Early research (Phase 1)Ended earlyNCT05987605
What this trial is testing

Phase I/II Clinical Study of 1A46 Drug Substance

Who this might be right for
Advanced Malignancies
BioRay Pharmaceutical Co., Ltd. 4
Large-scale testing (Phase 3)Study completedNCT02747043
What this trial is testing

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

Who this might be right for
Lymphoma, Non-Hodgkin
Amgen 256
Early research (Phase 1)Ended earlyNCT06248086
What this trial is testing

Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Who this might be right for
B-cell Lymphoma
Astellas Pharma Global Development, Inc. 1
Testing effectiveness (Phase 2)Study completedNCT01007292
What this trial is testing

YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Who this might be right for
Non-Hodgkin's Lymphoma
Astellas Pharma Inc 43
Testing effectiveness (Phase 2)Study completedNCT00290667
What this trial is testing

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Who this might be right for
Lymphoma
German High-Grade Non-Hodgkin's Lymphoma Study Group 586
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07035379
What this trial is testing

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)
Zhejiang Teruisi Pharmaceutical Inc. 66
Early research (Phase 1)Study completedNCT00556699
What this trial is testing

SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Genentech, Inc. 22
Early research (Phase 1)Study completedNCT02776813
What this trial is testing

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Lymphoma
Cogent Biosciences, Inc. 34
Early research (Phase 1)Ended earlyNCT02483000
What this trial is testing

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Who this might be right for
Burkitt LymphomaCD20-Positive Neoplastic Cells PresentDiffuse Large B-Cell Lymphoma+4 more
Fred Hutchinson Cancer Center 3
Early research (Phase 1)Study completedNCT02945215
What this trial is testing

Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

Who this might be right for
B-Cell Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 181
Testing effectiveness (Phase 2)Study completedNCT00070018
What this trial is testing

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
SWOG Cancer Research Network 46
Next Page